New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Once‐daily deferasirox dispersible tablets (DT) have a well‐defined safety and efficacy profile and, compared with parenteral deferoxamine, provide greater patient adherence, satisfaction, and quality of life. However, barriers still exist to optimal adherence, including gastrointestinal tolerabilit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Am J Hematol
Hauptverfasser: Taher, Ali T., Origa, Raffaella, Perrotta, Silverio, Kourakli, Alexandra, Ruffo, Giovan Battista, Kattamis, Antonis, Goh, Ai‐Sim, Cortoos, Annelore, Huang, Vicky, Weill, Marine, Merino Herranz, Raquel, Porter, John B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Research Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585741/
https://ncbi.nlm.nih.gov/pubmed/28142202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24668
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge